March 5, 2008 - Synvista Therapeutics, Inc. (Amex: SYI) announces the publication of a pre-planned sub-analysis from the ICARE study demonstrating that the addition of vitamin E to statin therapy prevented more cardiovascular events (heart attack, stroke and cardiovascular death) than statin therapy alone in patients with Diabetes Mellitus (DM) who tested positive for a genetic marker called Haptoglobin 2-2 (Hp2-2). This sub-analysis was published in the March issue of Arteriosclerosis, Thrombosis and Vascular Biology, a journal of the American Heart Association."These data are significant because they demonstrate that Haptoglobin testing may help physicians tailor optimal therapy for patients with diabetes who may be at risk for cardiovascular events. Physicians can better describe to their patients whether they are at high risk for a heart attack and whether they may anticipate a lower risk for heart attack if they take vitamin E... Synvista's Press Release -
